Sandoz Sunitinib 50 mg (Sunitinib CAPSULE) 50 MG

Sandoz Sunitinib 50 mg capsules are a pharmaceutical product used for targeted therapy. This medication is designed to support specific treatment protocols as prescribed by healthcare professionals.

Strength

50 MG

Manufacturer / TM Owner

SANDOZ CANADA INCORPORATED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Sunitinib is a type of medication known as a tyrosine kinase inhibitor. It is commonly used in the management of certain types of cancer, including renal cell carcinoma and gastrointestinal stromal tumors. The primary function of Sunitinib is to interfere with the growth and spread of cancer cells. Patients should consult their healthcare provider to understand the specific uses of Sunitinib 50 mg capsules.

Side Effects

Common effects of Sunitinib may include fatigue, nausea, and diarrhea. Some individuals might experience changes in blood pressure or skin discoloration. It is important to monitor these effects and discuss any concerns with a healthcare professional.

Precautions & Warnings

Sunitinib should be handled with care and stored as directed. It is essential to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients with pre-existing conditions or allergies should inform their doctor before starting Sunitinib.

Avoid Interactions

Sunitinib may interact with certain medications, including those metabolized by the liver's cytochrome P450 enzymes. It is advisable to avoid grapefruit and grapefruit juice, as they can affect the metabolism of Sunitinib. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

Sunitinib is primarily used in the treatment of certain types of cancer, such as renal cell carcinoma and gastrointestinal stromal tumors.

Sunitinib 50 mg capsules should be taken orally, typically once daily, as directed by a healthcare professional.

Common side effects of Sunitinib may include fatigue, nausea, diarrhea, and changes in blood pressure.

Sunitinib may interact with certain medications, so it is important to consult a healthcare provider before combining it with other drugs.

Patients should follow the prescribed dosage and inform their healthcare provider about any pre-existing conditions or allergies.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.